Deutsche Märkte öffnen in 4 Stunden 46 Minuten

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
281,19-4,07 (-1,43%)
Börsenschluss: 4:00PM EDT
281,30 +0,11 (+0,04%)
Nachbörse: 07:54PM EDT
Melden Sie sich an, um eine Nachricht zu posten.
  • S
    SAVAge
    $SAVA conversation
    On Monday, June 7th, $BIIB announced FDA Accelerated Approval of its Alzheimer's medication. The market cap increased by $17 billion! On June 24th, $LLY announced FDA Breakthrough Therapy Designation of Their Alzheimer's medication. The market cap increased by $15 billion. Last Friday, Roche announced the FDA Breakthrough Therapy Designation of its Alzheimer's medication. Its market cap increased by $13 billion. SAVA's Market cap sits at $2 billion. If the market cap increases by the Median ($15 billion), the SP will 8.5x. Oh, did I mention the above changes happened on ONE trading day? It did. Full post on FDA approval odds linked below. https://www.reddit.com/.../sava_will_85x_when_it.../
  • S
    SAVAge
    Cassava Sciences, Inc.
    Great Reddit Post:
    Valuation:  
    On Monday, June 7th, $BIIB announced FDA Accelerated Approval of ADUHELM (Alzheimer's medication, AD). The market cap went up to $17 Billion.

    On June 24th, $LLY announced the FDA Breakthrough Therapy Designation of Donanemab (Another AD medication). The market cap increased by $15 billion. 
     
    If SAVA announces a fast-track process for approval of its Alzheimer's (AD) medication, assuming it increases by 15 billion (like lly), that would be an 8.5x move in ONE DAY!

    I'll explain why Cassava has an excellent chance at being fast-tracked (soon) but let me highlight two key points first:    

    1) The above catalysts were NOT FDA approval; They were announcements that FDA approval was fast-tracked.  
    2) SAVA's AD medication has achieved what BIIB and LLY can only fantasize about. It is far superior to both. I'll provide data for that to make it clear. 
    As the above is related to valuation, I'll throw in that you want to read more about valuation; see the Seeking Alpha article below. 
    https://www.reddit.com/r/wallstreetbets/comments/pz6w8h/sava_cause_more_wrinkle/?utm_medium=android_app&utm_source= click on the link to finish reading.
    71 votes and 118 comments so far on Reddit
    71 votes and 118 comments so far on Reddit
    www.reddit.com
  • O
    O-Behave
    $FDX conversation
    $FDX hit is 52WKLOW today!? revenue rose to 14% to $22 billion!! It's being treated as if revenues crashed!🤦 ABSOLUTELY NO WAY it stays this low for long. A MASSIVE DARK POOL BUY worth $53 million hit today. It's free money at $229 folks WATCH IT move at LEAST $10 by next Friday. Set it and forget it.

    $BIIB yesterday I told traders about the $48 million dark pool BUY, today it was 17 cents from breaking $300. $BIIB could be at $330+ by next Friday. HUGE NEWS BY FDA went unnoticed but it was MAJOR because it dispelled the NUMBER ONE BASH of $BIIB haters. FDA has officially added "Reduction in amyloid beta plaques" to its table of surrogate endpoints! Soooo WHY isnt $BIIB trading at $400+ today since the opposite sentiment that FDA shouldn't have approved it b/c it doesn't work crashed it? All the $BIIB should be handing under a rock🪨 right about now. THE GAME HAS CHANGED. BULLISH💸📈
  • s
    sat
    $SAVA conversation
    $sava $biib who is better
  • s
    stocktargetadvisor
    $BIIB conversation
    $BIIB
    Target Lowered by Stifel Nicolaus Buy USD 430 » USD 344
    Target Lowered by Cantor Fitzgerald Neutral USD 427 » USD 327
  • O
    O-Behave
    $BIIB conversation
    $BIIB IS TRENDING! Traders who never even traded it are joining the party 🥳 today. WOW. BULLISH
    The shares of Biogen Inc (NASDAQ:BIIB) are up 2.7% at $297 this morning, following a bull note from Needham. The analyst in question initiated coverage of the stock with a "buy" rating and a $400 price target, citing Alzheimer drug Aduhelm as a big seller in the long term as it predicted more than $6 billion in sales across the globe.

    Needham joins a split brokerage bunch, though there is reason to believe that its bull note could be just the beginning for Biogen stock. Heading into today, 13 considered BIIB a "buy" or better, compared to 14 calling it a "hold." Meanwhile, the equity's 12-month consensus price target of $416.37 is a 39% premium to current levels.

    Call activity is ramping up in response to the analyst attention. So far today, Biogen's normally quiet options pits have seen 1,755 calls exchange hands, which is double the intraday average, and more than three times the amount of puts across the tape. The most popular contract is the 9/24 300-strike call, where positions are being opened.

    That bullish sentiment has been the norm as of late. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Biogen stock sports a 10-day call/put volume ratio of 2.60, which stands higher than 88% of readings in its annual range. This means calls have been picked up at a quicker-than-usual rate in the last two weeks.

    What's more, BIIB options can still be had at a bargain. This is per the stock's Schaeffer's Volatility Index (SVI) of 35%, which stands higher than just 6% of readings from the past 12 months. This means options traders are pricing in relatively low volatility expectations for the equity at the moment.

    On the charts, Biogen stock has trended lower since the Food and Drug Administration (FDA) approved Aduhelm in June, losing over 30% between its June 7 record high of $468.55 and yesterday's low. The 320-day moving average has remained in place as a layer of support, though, and BIIB boasts a 21.4% year-to-date lead.
  • O
    O-Behave
    $BIIB conversation
    $BIIB ADDED!
  • O
    O-Behave
    $BIIB conversation
    What price do you think $BIIB would be at in 6 months if it's phase 3 drug for ALS got FDA approved? I'll go 1st $2000
  • O
    O-Behave
    $BIIB conversation
    $BIIB RSI IS AT 11.35!!! A bullish investor could look at BIIB's 21.2 RSI reading as a sign that recent heavy selling is in the process of exhausting itself & begin to look for entry point opportunities on the buy side.
    https://www.stockrsi.com/biogen/
    Biogen RSI charts and information, presented by Stock RSI
    Biogen RSI charts and information, presented by Stock RSI
    www.stockrsi.com
  • O
    O-Behave
    $BIIB conversation
    $BIIB is trading at price BEFORE FDA approval. THINGS COULDN'T POSSIBLY BE THIS BAD REGARDLESS OF HOW HARD THE SMEAR IS. Free money.
  • O
    O-Behave
    $BIIB conversation
    $BIIB u can bash the price of the drug, whether it works or not, some even say it wasn't #FDA approved!🤣 1 thing they can't deny is that it has 1 of the most SOLID FUNDAMENTALS in #biotech
  • O
    O-Behave
    $BIIB conversation
    99% of traders don't even KNOW that $BIIB is in phase 3 for a drug to assist in ALS!! Can u IMAGINE if that were to get FDA approved? I mean WHEN it gets approved? $700 per share? KEEP SLEEPING
  • O
    O-Behave
    $BIIB conversation
    cowen washington research group - 'Medicaid is reinforcing to states that Biogen/Eisai’s Aduhelm for Alzheimer’s
    disease must be a covered outpatient drug as the manufacturer has a drug rebate
    agreement with the program.'

    $BIIB https://t.co/DOQHJM74XO
  • O
    O-Behave
    $BIIB conversation
    $BIIB ummm look how HARD it's bouncing. Wasn't it just at $285 an hour ago. LMFAOOOOO! FREE MONEY 💸✈📈📚🛒
  • O
    O-Behave
    $BIIB conversation
    $BIIB one of the most oversold stocks I. The S&P 500, RSI IS AT 10.8!! Extremely oversold
  • O
    O-Behave
    $BIIB conversation
    $BIIB they're loading this dip I'm bulk. Slow roll out of drug was ALREADY WARNED by MANAGEMENT weeks ago! Everything already baked in since the $340s. Easy money. https://twitter.com/aaaamhim/status/1440780889076555782?s=19
  • O
    O-Behave
    $PFE conversation
    More and more people getting vaccinated. $PFE is WAY UNDERVALUED. $BIIB also beyond oversold. $BIIB had great news today, it's finally hitting eyes. Gonna run imo
  • O
    O-Behave
    $BIIB conversation
    $BIIB #ALS drug is in phase 3! How come no one is talking about it?! Can you imagine? https://www.biogen.com/en_us/als-community-update.html
    Update on Tofersen Clinical Program
    www.biogen.com
  • s
    stocktargetadvisor
    $BIIB conversation
    $BIIB
    Initiated by Mizuho Securities Hold USD 300
    Initiates Coverage On Needham & Company LLC Buy USD 400
  • O
    O-Behave
    $BIIB conversation
    $BIIB breaking out. Looking so STRONG. I'm loving this! Let's get to $340 by Friday. Let this news marinate